Adriana Rico1, Lori A Pollack1, Trevor D Thompson1, Mei-Chin Hsieh2, Xiao-Cheng Wu2, Jordan J Karlitz3, Dee W West4, John M Rainey5, Vivien W Chen2. 1. Cancer Surveillance Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, United States. 2. Louisiana Tumor Registry and Epidemiology Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States. 3. Division of Gastroenterology, Tulane University School of Medicine, New Orleans, Louisiana, United States. 4. Cancer Registry of Greater California, Public Health Institute, Sacramento, California, United States. 5. Acadiana Medical Research Foundation, Lafayette, Louisiana, United States.
Abstract
BACKGROUND: In 2011, the National Comprehensive Cancer Network (NCCN) recommended KRAS testing for metastatic colorectal cancer (mCRC) patients. Our study assessed KRAS testing prevalence and its association with socio-demographic and clinical factors and examined first-line treatment. METHODS: Ten state population-based registries supported by Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) collected detailed cancer information on mCRC cases diagnosed in 2011, including KRAS biomarker testing and first-line treatment from ten central cancer registries. Data were analyzed with Chi-square tests and multivariate logistic regression. RESULTS: Of the 3,608 mCRC cases, 27% (n = 992) had a documented KRAS test. Increased age at diagnosis (p < 0.0001), racial/ethnic minorities (p = 0.0155), public insurance (p = 0.0018), and lower census tract education (p = 0.0023) were associated with less KRAS testing. Significant geographic variation in KRAS testing (p < 0.0001) ranged from 46% in New Hampshire to 18% in California. After adjusting for all covariates, age and residence at diagnosis (both p < 0.0001) remained predictors of KRAS testing. Non-Hispanic Blacks had less KRAS testing than non-Hispanic Whites (OR = 0.77, 95% CI = 0.61-0.97). Among those tested and found to have normal (wild-type) KRAS, 7% received anti-EGFR treatment; none received such treatment among those with KRAS mutated gene. CONCLUSIONS: Despite NCCN guideline recommendations, 73% of mCRC cases diagnosed in 2011 had no documented KRAS test. Disparities in KRAS testing existed based on age, race, and residence at diagnosis. IMPACT: These findings show the capacity of monitoring KRAS testing in the US using cancer registry data and suggest the need to understand the low uptake of KRAS testing, and associated treatment choices during the first year since diagnosis.
BACKGROUND: In 2011, the National Comprehensive Cancer Network (NCCN) recommended KRAS testing for metastatic colorectal cancer (mCRC) patients. Our study assessed KRAS testing prevalence and its association with socio-demographic and clinical factors and examined first-line treatment. METHODS: Ten state population-based registries supported by Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) collected detailed cancer information on mCRC cases diagnosed in 2011, including KRAS biomarker testing and first-line treatment from ten central cancer registries. Data were analyzed with Chi-square tests and multivariate logistic regression. RESULTS: Of the 3,608 mCRC cases, 27% (n = 992) had a documented KRAS test. Increased age at diagnosis (p < 0.0001), racial/ethnic minorities (p = 0.0155), public insurance (p = 0.0018), and lower census tract education (p = 0.0023) were associated with less KRAS testing. Significant geographic variation in KRAS testing (p < 0.0001) ranged from 46% in New Hampshire to 18% in California. After adjusting for all covariates, age and residence at diagnosis (both p < 0.0001) remained predictors of KRAS testing. Non-Hispanic Blacks had less KRAS testing than non-Hispanic Whites (OR = 0.77, 95% CI = 0.61-0.97). Among those tested and found to have normal (wild-type) KRAS, 7% received anti-EGFR treatment; none received such treatment among those with KRAS mutated gene. CONCLUSIONS: Despite NCCN guideline recommendations, 73% of mCRC cases diagnosed in 2011 had no documented KRAS test. Disparities in KRAS testing existed based on age, race, and residence at diagnosis. IMPACT: These findings show the capacity of monitoring KRAS testing in the US using cancer registry data and suggest the need to understand the low uptake of KRAS testing, and associated treatment choices during the first year since diagnosis.
Entities:
Keywords:
KRAS testing; NPCR registries; colorectal cancer
Authors: Linda C Harlan; Amanda L Greene; Limin X Clegg; Margaret Mooney; Jennifer L Stevens; Martin L Brown Journal: J Clin Oncol Date: 2005-11-21 Impact factor: 44.544
Authors: Mary E Charlton; Jordan J Karlitz; Jennifer A Schlichting; Vivien W Chen; Charles F Lynch Journal: Am J Clin Oncol Date: 2017-10 Impact factor: 2.339
Authors: Vivien W Chen; Christie R Eheman; Christopher J Johnson; Monique N Hernandez; David Rousseau; Timothy S Styles; Dee W West; Meichin Hsieh; Anne M Hakenewerth; Maria O Celaya; Randi K Rycroft; Jennifer M Wike; Melissa Pearson; Judy Brockhouse; Linda G Mulvihill; Kevin B Zhang Journal: J Registry Manag Date: 2014
Authors: Eric Van Cutsem; Heinz-Josef Lenz; Claus-Henning Köhne; Volker Heinemann; Sabine Tejpar; Ivan Melezínek; Frank Beier; Christopher Stroh; Philippe Rougier; J Han van Krieken; Fortunato Ciardiello Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544
Authors: Ajay S Behl; Katrina A B Goddard; Thomas J Flottemesch; David Veenstra; Richard T Meenan; Jennifer S Lin; Michael V Maciosek Journal: J Natl Cancer Inst Date: 2012-11-28 Impact factor: 13.506
Authors: Meinolf Karthaus; Ralf-Dieter Hofheinz; Laurent Mineur; Henry Letocha; Richard Greil; Josef Thaler; Eva Fernebro; Kelly S Oliner; Michael Boedigheimer; Brian Twomey; Ying Zhang; Gaston Demonty; Claus-Henning Köhne Journal: Br J Cancer Date: 2016-10-20 Impact factor: 7.640
Authors: Daniel J Becker; Kyung M Lee; Steve Y Lee; Kristine E Lynch; Danil V Makarov; Scott E Sherman; Christy D Morrissey; Michael J Kelley; Julie A Lynch Journal: JCO Precis Oncol Date: 2021-04-13
Authors: E Aranda; E Polo; C Camps; A Carrato; E Díaz-Rubio; V Guillem; R López; A Antón Journal: Clin Transl Oncol Date: 2020-01-23 Impact factor: 3.405
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775